Compare Meta Platforms Inc (META) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Meta Platforms Inc trades at $645.73 (market cap $1.64T), while Vertex Pharmaceuticals Incorporated trades at $481.99 (market cap $121.95B). The key difference: Meta Platforms Inc is far larger — about 13.4× Vertex Pharmaceuticals Incorporated's market cap, and Meta Platforms Inc pays a 0.33% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| META | VRTX | |
|---|---|---|
Market Cap | $1.64T | $121.95B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $529.59 |
52-Week Low | $525.72 | $366.54 |
Enterprise Value | $1.65T | $116.69B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $646.96, up 0.15% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected, driven by robust revenue growth and a net income margin of 32.84%. Recent developments include the launch of the Muse Spark AI model and a dividend payment scheduled for June 2026.
The outlook remains positive with analyst consensus pointing to a $817.32 price target and 79% buy ratings. Key opportunities include AI innovation and revenue expansion, while risks involve regulatory lawsuits and high capital expenditures. The stock's valuation at a P/E of 23.49 appears reasonable given growth prospects, but investors should monitor legal and competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
